Related Experiment Video
Updated: Jul 19, 2026
05:44
Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
Published on: October 13, 2023
Italian Multiple Sclerosis Database Network
M Trojano1, D Paolicelli, V Lepore
1Department of Neurological and Psychiatric Sciences, University of Bari, Piazza Giulio Cesare 11, I-70124 Bari, Italy. mtrojano@neurol.uniba.it
Summary
Long-term interferon beta (IFNbeta) treatment significantly reduces disability progression in multiple sclerosis (MS) patients. Early and sustained use of IFNbeta offers substantial benefits for managing MS long-term.
Area of Science:
- Neurology
- Immunology
- Clinical Research
Background:
- The Multiple Sclerosis Database Network (MSDN) is Italy's first MS registry.
- Understanding long-term treatment effects is crucial for managing multiple sclerosis (MS).
Purpose of the Study:
- To evaluate the long-term effectiveness of interferon beta (IFNbeta) on disability progression in MS patients.
- To compare disability progression between patients with varying durations of IFNbeta exposure and untreated patients.
Main Methods:
- Analysis of data from the MSDN cohort, including a sample of 2090 MS patients.
- Comparison of disability progression (EDSS score change) in IFNbeta-treated versus untreated relapsing-remitting MS patients (subset of 1170 patients).
Main Results:
- Patients exposed to IFNbeta for over 4 years showed a 4- to 5-fold reduced risk of disability progression compared to those exposed for up to 2 years.
- IFNbeta-treated patients experienced a differential reduction in EDSS score change of -0.055 per year versus untreated patients.
Conclusions:
- IFNbeta treatment demonstrates significant effectiveness in reducing long-term disability progression in multiple sclerosis.
- Sustained use of IFNbeta is associated with better outcomes in managing MS-related disability.
